Jessica Morris Net Worth

The estimated Net Worth of Jessica Edgar Morris is at least 246$ dollars as of 14 June 2018. Ms. Morris owns over 300 units of Tonix Pharmaceuticals Corp stock worth over 246$ and over the last 9 years she sold TNXP stock worth over 0$. In addition, she makes 0$ as Chief Operating Officer at Tonix Pharmaceuticals Corp.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms. Morris TNXP stock SEC Form 4 insiders trading

Jessica has made over 1 trades of the Tonix Pharmaceuticals Corp stock since 2018, according to the Form 4 filled with the SEC. Most recently she bought 300 units of TNXP stock worth 1,257$ on 14 June 2018.

The largest trade she's ever made was buying 300 units of Tonix Pharmaceuticals Corp stock on 14 June 2018 worth over 1,257$. On average, Jessica trades about 27 units every 0 days since 2016. As of 14 June 2018 she still owns at least 1,638 units of Tonix Pharmaceuticals Corp stock.

You can see the complete history of Ms. Morris stock trades at the bottom of the page.

Jessica Morris biography

Jessica Edgar Morris serves as Chief Operating Officer of the Company. She has worked for the Company since April 2013, first as a consultant (April 2013 – September 2013), then as SVP of Finance (September 2013 – October 2015), followed by Chief Administrative Officer (October 2015 – January 2016), Acting Chief Financial Officer (January 2016 – February 2016), and Executive Vice President, Operations (February 2016 – January 2018). Prior to joining the Company, Ms. Morris was a Vice President in investment management at Zhong Rong Group. Previously, Ms. Morris was a Senior Associate in the Sponsor Finance Group at American Capital, a Vice President of the mezzanine debt fund at Calvert Street Capital Partners, an Associate in the commercial finance department of Silicon Valley Bank, and a Financial Analyst in the investment banking group at Deutsche Bank. Ms. Morris earned a B.S. in Commerce and a B.A. in Music from the University of Virginia, where she was an Echols Scholar.

How old is Jessica Morris?

Jessica Morris is 42, she's been the Chief Operating Officer of Tonix Pharmaceuticals Corp since 2018. There are 15 older and no younger executives at Tonix Pharmaceuticals Corp. The oldest executive at Tonix Pharmaceuticals Holding Corp is Adeoye Olukotun, 75, who is the Independent Director.

What's Jessica Morris's mailing address?

Jessica's mailing address filed with the SEC is C/O TONIX PHARMACEUTICALS HOLDING CORP., 26 MAIN ST., SUITE 101, CHATHAM, NJ, 07928.

Insiders trading at Tonix Pharmaceuticals Corp

Over the last 12 years, insiders at Tonix Pharmaceuticals Corp have traded over 155,884$ worth of Tonix Pharmaceuticals Corp stock and bought 1,820,071 units worth 3,399,062$ . The most active insiders traders include Ernest Mario、Seth Lederman、Bruce Daugherty. On average, Tonix Pharmaceuticals Corp executives and independent directors trade stock every 32 days with the average trade being worth of 2,734$. The most recent stock trade was executed by Seth Lederman on 29 June 2022, trading 20,000 units of TNXP stock currently worth 34,200$.

What does Tonix Pharmaceuticals Corp do?

tonix is developing innovative pharmaceutical products to address major public health challenges. in addition to tonmya for ptsd, tonix is developing tnx-601 (tianeptine oxalate), a clinical candidate at pre-ind (investigational new drug) application stage, designed as a daytime treatment for ptsd and tnx-801, a live synthetic version of horsepox virus, at the pre-ind application stage, to be developed as a potential smallpox-preventing vaccine. further information about tonix can be found at www.tonixpharma.com.

Complete history of Ms. Morris stock trades at Tonix Pharmaceuticals Corp

Tonix Pharmaceuticals Corp executives and stock owners

Tonix Pharmaceuticals Corp executives and other stock owners filed with the SEC include:

• Seth Lederman,
  Chairman of the Board, President, Chief Executive Officer
• Dr. Seth Lederman M.D.,
  Co-Founder, Pres, CEO & Chairman
• Dr. Seth Lederman,
  Co-Founder, Pres, CEO & Chairman
• Dr. Gregory M. Sullivan M.D.,
  Chief Medical Officer & Sec.
• Gregory Sullivan,
  Secretary, Chief Medical Officer
• Bradley Saenger CPA, CPA,
  CFO & Treasurer
• Bradley Saenger,
  Chief Financial Officer, Treasurer
• Richard Bagger,
  Director
• Herbert Harris,
  Executive Vice President - Translational Medicine
• David Grange,
  Independent Director
• Margaret Bell,
  Independent Director
• James Treco,
  Lead Independent Director
• Adeoye Olukotun,
  Independent Director
• Daniel Goodman,
  Independent Director
• Jessica Morris,
  Chief Operating Officer
• Dr. Sina Bavari Ph.D.,
  Exec. VP of Infectious Disease R&D
• Dr. Anthony Macaluso Ph.D.,
  Exec. VP of Strategic Devel.
• Dr. Darryl Rideout Ph.D.,
  Exec. VP of Experimental Chemistry
• Siobhan Fogarty B.Sc., M.Sc.,
  Exec. VP of Product Devel.
• Dr. Bruce L. Daugherty M.B.A., Ph.D.,
  Exec. VP of Research
• Dr. Herbert W. Harris M.D., Ph.D.,
  Exec. VP of Translational Medicine
• Dr. R. Michael Gendreau,
  Consultant
• Dr. Daniel J. Clauw M.D.,
  Consultant
• Dr. Ronald R. Notvest,
  Exec. VP of Commercial Planning and Devel.
• Jessica Edgar Morris,
  Chief Operating Officer
• Charles E Iv Mather,
  Director
• Ernest Mario,
  Director
• John B Rhodes,
  Director
• Samuel R Saks,
  Director
• Patrick P Grace,
  Director
• Bruce Daugherty,
  See Remarks
• Stuart Davidson,
  Director
• Donald J Kellerman,
  See Remarks
• Leland Gershell,
  CFO and Treasurer
• Carolyn E. Taylor,
  Director
• Richard Newcomb Stillwell,
  Director